View Older Stories

Mar 11, 2026 11:51AM REGENXBIO reports interim data for Duchenne gene therapy RGX-202

Mar 9, 2026 07:46AM Truist on Head of CBER at FDA Exit: 'we anticipate a positive stock reaction for IRON CAPT RGNX QURE'

Mar 9, 2026 06:49AM Regenxbio Inc. (RGNX) PT Lowered to $30 at H.C. Wainwright

Mar 6, 2026 08:20AM Regenxbio Inc. (RGNX) PT Lowered to $18 at Leerink Partners

Mar 5, 2026 05:17PM Clear Street Reiterates Buy Rating on Regenxbio Inc. (RGNX): "market is overly discounting the strength of early ‘202 data"

Mar 5, 2026 02:52PM Regenxbio Inc. (RGNX) PT Lowered to $17 at Morgan Stanley

Mar 5, 2026 02:11PM Regenxbio Inc. (RGNX) PT Lowered to $42 at Stifel

Mar 5, 2026 07:06AM Regenxbio (RGNX) Misses Q4 EPS by 58c

Feb 26, 2026 11:53AM Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'

Feb 11, 2026 06:40AM Regenxbio Inc. (RGNX) PT Lowered to $32 at H.C. Wainwright

Feb 10, 2026 06:32AM Regenxbio Inc. (RGNX) PT Lowered to $12 at Goldman Sachs

Feb 9, 2026 04:41PM After-hours movers: ON Semiconductor, Credo, Upwork, Regenxbio, and more

Feb 9, 2026 04:05PM REGENXBIO receives FDA rejection letter for gene therapy RGX-121

Feb 9, 2026 04:01PM Regenxbio (RGNX) Halted, News Pending

Jan 29, 2026 06:50AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Jan 29, 2026 04:44AM Goldman Sachs Reiterates Neutral Rating on Regenxbio Inc. (RGNX)

Jan 29, 2026 04:26AM Baird on Regenxbio Inc. (RGNX): 'Incrementally negative on program update'

Jan 28, 2026 01:51PM Stifel on Regenxbio Inc. (RGNX): PT $45, 'should NOT impact RGX-202 and RGX-314'

Jan 28, 2026 07:30AM FDA places clinical hold on REGENXBIO gene therapies after tumor case

Jan 12, 2026 06:53AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Jan 12, 2026 04:00AM Baird on Regenxbio Inc. (RGNX): 'Incrementally positive on 2026 update'

Jan 7, 2026 09:00PM BofA top picks in biotech as sector heading for recovery in 2026

Dec 19, 2025 07:44AM Regenxbio Inc. (RGNX) PT Raised to $45 at Stifel: Lead Programs Have 2026 Catalysts

Dec 15, 2025 06:20AM Regenxbio Inc. (RGNX) PT Raised to $20 at Leerink Partners

Nov 26, 2025 04:17PM Regenxbio (RGNX) files mixed shelf

Nov 6, 2025 07:22AM Regenxbio (RGNX) Tops Q3 EPS by 10c

Oct 30, 2025 07:05AM REGENXBIO completes pivotal trial enrollment for duchenne gene therapy

Oct 7, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Oct 6, 2025 07:05AM REGENXBIO completes enrollment in pivotal wet AMD gene therapy trials

Sep 8, 2025 07:14AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Sep 5, 2025 03:21PM Goldman Sachs Reiterates Neutral Rating on Regenxbio Inc. (RGNX)

Sep 5, 2025 11:03AM Raymond James on Regenxbio Inc. (RGNX): 'we think FDA guidance is strongly supportive of HS D2S6 as a biomarker'

Sep 5, 2025 07:05AM REGENXBIO reports sustained biomarker reduction in MPS II gene therapy trial

Aug 19, 2025 06:48AM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Aug 19, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Aug 18, 2025 05:00PM REGENXBIO receives FDA review extension for MPS II gene therapy

Aug 8, 2025 08:52AM Regenxbio Inc. (RGNX) PT Lowered to $17 at RBC Capital

Aug 7, 2025 11:56AM Raymond James Reiterates Outperform Rating on Regenxbio Inc. (RGNX)

Aug 7, 2025 07:13AM Regenxbio (RGNX) Misses Q2 EPS by 44c

Aug 7, 2025 07:00AM REGENXBIO to start pivotal trial for diabetic retinopathy treatment

Jul 10, 2025 11:55AM REGENXBIO publishes preclinical data on RGX-202 gene therapy construct

Jun 6, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Jun 5, 2025 01:21PM Morgan Stanley on Regenxbio Inc. (RGNX): 'we continue to appreciate RGNX’s diversified mid- to late-stage gene therapy pipeline'

Jun 5, 2025 01:15PM Leerink on Regenxbio Inc. (RGNX): 'the path to accelerated approval is likely clear, valuation is undemanding, and balance sheet robust'

Jun 5, 2025 12:26PM Raymond James Defending Regenxbio Inc. (RGNX): 'we see this as a good entry point'

Jun 5, 2025 12:25PM BofA Securities Defending Regenxbio Inc. (RGNX), Shares Down 15pct

Jun 5, 2025 12:14PM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX) Following DMD data

Jun 5, 2025 07:05AM Regenxbio (RGNX) Reports New Data from Phase I/II Affinity Trial

May 20, 2025 08:05AM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)

May 19, 2025 04:05PM Regenxbio (RGNX) Announces Strategic Royalty Monetization Agreement for Up to $250 Million

View Older Stories